{"disease":{"id":"b-cell-follicular-lymphoma","name":"b cell follicular lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06339255","title":"Italian Observational Study on CAR-T Therapy for Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":5300,"lead_sponsor_name":"Paolo Corradini","has_results":false},{"nct_id":"NCT05978141","title":"A Registry for People With T-cell Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02793583","title":"Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":710,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01311232","title":"Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab","phase":"","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04858568","title":"Immune Responses to COVID-19 Vaccination in Lymphoma Patients","phase":"","overall_status":"COMPLETED","enrollment_count":592,"lead_sponsor_name":"University Hospital Southampton NHS Foundation Trust","has_results":false},{"nct_id":"NCT04663347","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":543,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT03375619","title":"Long-term Follow-up Study of Patients Receiving CAR-T Cells","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Medical College of Wisconsin","has_results":false},{"nct_id":"NCT06785818","title":"Long-term Follow up Local Registry Study of Kymriah in South Korea","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04799275","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","phase":"PHASE2, PHASE3","overall_status":"SUSPENDED","enrollment_count":422,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04952974","title":"B-cell Chronic Lymphoid Malignancies Markers","phase":"","overall_status":"UNKNOWN","enrollment_count":420,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT01897571","title":"Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Epizyme, Inc.","has_results":true},{"nct_id":"NCT05633615","title":"Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":396,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT02631044","title":"Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":false},{"nct_id":"NCT01799889","title":"Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":326,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04594642","title":"A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT01321541","title":"Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":312,"lead_sponsor_name":"CTI BioPharma","has_results":true},{"nct_id":"NCT02348216","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":307,"lead_sponsor_name":"Kite, A Gilead Company","has_results":true},{"nct_id":"NCT03314974","title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06526793","title":"Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05541341","title":"Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03501576","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT01953692","title":"A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":197,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03162536","title":"A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":190,"lead_sponsor_name":"ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)","has_results":false},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04803201","title":"Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":170,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03997968","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Cyteir Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT04870853","title":"Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06142188","title":"Relmacabtagene Autoleucel in Hematologic Malignancies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Shanghai Ming Ju Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT05294731","title":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":146,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT04058470","title":"Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":140,"lead_sponsor_name":"Huiqiang Huang","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT07197307","title":"Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Universität Münster","has_results":false},{"nct_id":"NCT00901615","title":"Lenalidomide and R-CHOP in B-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Lymphoma Study Association","has_results":false},{"nct_id":"NCT01193842","title":"Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06782854","title":"Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the \"Off the Beaten Track\" Liquid Biopsy","phase":"","overall_status":"COMPLETED","enrollment_count":102,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03097770","title":"Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT07473167","title":"Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"TICAROS Co., Ltd.","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04089215","title":"CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":82,"lead_sponsor_name":"Shanghai Ming Ju Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT00723099","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT01693614","title":"Safety and Efficacy of BKM120 in Relapsed and Refractory NHL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03424603","title":"Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT03676504","title":"Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"University Hospital Heidelberg","has_results":false},{"nct_id":"NCT02332980","title":"Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT05040555","title":"R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden","phase":"NA","overall_status":"RECRUITING","enrollment_count":64,"lead_sponsor_name":"oubai, MD/PhD","has_results":false},{"nct_id":"NCT00856388","title":"Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04195633","title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}